Tiziana Life Sciences pursuing development of intranasal foralumab for Long COVID treatment

–News Direct–

Tiziana Life Sciences chief medical officer Dr Matthew Davis joins Proactive's Natalie Stoberman to explain how the company is pursuing the development of intranasal foralumab for the treatment of Long COVID.

Davis says Tiziana intends to enter into a three-month Phase 2a placebo-controlled clinical trial to research how foralumab’s well-established role in de-activating microglia cells could treat or reduce the symptoms of Long COVID.

Contact Details

Proactive Investors

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/tiziana-life-sciences-pursuing-development-of-intranasal-foralumab-for-long-covid-treatment-591916922